Context Therapeutics Inc. (CNTX) stock
CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.17+0.01 (+3.07%)
Close on Nov 17, 2026Market cap $15.71MP/E –Yield –
Context Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Context Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$33.97M. For fiscal 2025 it was -$26.39M. The highest annual figure on record is -$1.03M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.39M | – |
| FY2024 | Dec 31, 2024 | -$14.56M | – |
| FY2023 | Dec 31, 2023 | -$21.05M | – |
| FY2022 | Dec 31, 2022 | -$13.55M | – |
| FY2021 | Dec 31, 2021 | -$8.80M | – |
| FY2020 | Dec 31, 2020 | -$1.03M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.02M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.03M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.73M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.93M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.82M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.63K | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.72M | – |
| Q4 FY2020 | Dec 31, 2020 | -$176.03K | – |
See a number that looks wrong?